BioNTech Shares Are Trading Higher After the Company Announced the FDA Allowed Its Partnered Phase 1 Trial for BNT326/YL202 to Resume.
BioNTech Shares Are Trading Higher After the Company Announced the FDA Allowed Its Partnered Phase 1 Trial for BNT326/YL202 to Resume.
BioNTech股票交易走高,因公司宣佈FDA允許其合作的BNT326/YL202第一階段試驗恢復。
BioNTech Shares Are Trading Higher After the Company Announced the FDA Allowed Its Partnered Phase 1 Trial for BNT326/YL202 to Resume.
BioNTech股票交易走高,因公司宣佈FDA允許其合作的BNT326/YL202第一階段試驗恢復。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。